Pasireotide in the treatment of neuroendocrine tumors: A review of the literature

Giovanni Vitale, Alessandra Dicitore, Concetta Sciammarella, Sergio Di Molfetta, Manila Rubino, Antongiulio Faggiano, Annamaria Colao

Research output: Contribution to journalReview articlepeer-review


Somatostatin analogs have an important role in the medical therapy of neuroendocrine tumors (NETs). Octreotide and lanreotide, both somatostatin analogs binding with high affinity for the somatostatin receptor (SSTR)2, can control symptoms in functional NETs. In addition, these compounds, because of their antiproliferative effects, can stabilize growth of well-differentiated NETs. Pasireotide is a novel multireceptor-targeted somatostatin analog with high affinity for SSTR1, 2, 3, and 5. This review provides an overview of the state of the art of pasireotide in the treatment of NETs, with the aim of addressing clinical relevance and future perspectives for this molecule in the management of NETs.

Original languageEnglish
Pages (from-to)R351-R364
JournalEndocrine-Related Cancer
Issue number6
Publication statusPublished - Jun 1 2018


  • Neuroendocrine tumors
  • Pasireotide
  • Somatostatin analogs
  • Somatostatin receptors

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research


Dive into the research topics of 'Pasireotide in the treatment of neuroendocrine tumors: A review of the literature'. Together they form a unique fingerprint.

Cite this